Search

everythinglearnresearchcommunity

for

Search:↓

Pelage PP405 is a new hair loss treatment in trials, potentially reactivating dormant hair follicles without affecting hormones. Results are expected in February 2025, offering an alternative to minoxidil and finasteride.

The potential of using a specific antibody, HMI-115, as a treatment for hair loss alongside traditional treatments such as minoxidil and finasteride. The user suggests trying either a 240 mg or 30 mg dose to see if it works.

Biotin is being misleadingly marketed as a primary treatment for androgenic alopecia, overshadowing more effective treatments like finasteride and minoxidil. There is a call for increased awareness and accountability to prevent misinformation.

PP405 is a new drug in Phase 2 trials for hair loss, generating cautious optimism among users. Some users are currently using finasteride and experiencing side effects, while others are skeptical about unapproved products being sold.

Ursolic acid, found in apple peels, lemongrass, rosemary, and lavender, may have anti-androgen effects similar to finasteride. It might be beneficial for hair health when used with other treatments like Minoxidil, Finasteride, and RU58841.

A poem humorously suggests hope for a new hair loss treatment, PP405, while users debate the effectiveness and side effects of current treatments like Finasteride. Concerns are raised about Finasteride's side effects, especially for young users, and skepticism about new treatments is expressed.

A naturally occurring sugar, 2-deoxy-D-ribose, in a hydrogel form, shows promise for hair regrowth similar to minoxidil in rats. The user plans to synthesize it for topical application, seeking input from others.

PP405 is moving to late-stage trials, showing potential for hair regrowth, with 31% of male patients experiencing a 20% increase in hair density. Veradermics is developing an oral minoxidil version, and there is interest in combining treatments for better results.

The conversation discusses potential advancements in two hair loss drugs, KX-826 and GT20029, and the interest in whether transitioning from oral finasteride to these drugs would maintain hair growth. One reply expresses skepticism about the compounds' representation.

The conversation is about making a solution of RU58841 using propanediol instead of propylene glycol due to skin irritation. The user seeks advice on whether this substitution is acceptable.

PP405, developed by Pelage Pharmaceuticals, can reactivate dormant hair follicle stem cells and increase hair growth by 20% in eight weeks, unlike minoxidil or finasteride. However, skepticism remains about its effectiveness and availability, with concerns about funding and the timeline for broader access.

A user is experiencing hair regrowth after treating vitamin D, B12, and B9 deficiencies, noticing some improvement after 9 months. They are unsure if further improvement will occur or if they have reached the end of progress, with a possibility of androgenetic alopecia (AGA) being suggested.

PP405 is being discussed as a potential new approach to hair loss by targeting follicle stem cells, suggesting a different mechanism from existing treatments like finasteride and minoxidil. However, there is skepticism about whether it will lead to meaningful long-term outcomes or follow the pattern of previous treatments that showed promise but lacked consistent results.

Minoxidil with alcohol and propylene glycol was more effective than non-alcohol versions, and RU58841 worked best in a non-water-based solution. Oral finasteride showed better results than topical, despite side effects; microneedling and tretinoin worsened hair loss, and PRP was only helpful when younger.

A study that outlines the full model for androgenic alopecia (AGA) which links DHT to cellular senescence in dermal papilla cells, and suggests black chokeberry as a source of cyanidin 3-O-arabinoside polyphenol with potential anti-oxidant properties that could reverse this process. The post encourages reaching out to experts in anti-aging and longevity to research treatments involving the polyphenol.

Pelage is delaying the start of phase 3 trials for PP405 to 2026 due to necessary regulatory processes, despite having $120 million in funding. Users discuss the potential of PP405 for hair regrowth, with some expressing skepticism and others hopeful for new treatments like Breezula.

Two Chinese suppliers provided legitimate RU58841, confirmed through a free drug testing service. The vendors were Shaanxi Greenyo Biotech and Lyphar, found on Made-in-China.

Hair loss treatments RU55841, CB-03-01, and Eucapil were discussed, with concerns about needing increased dosages over time and potential side effects. A user suggested that CB's results could be due to various factors and that combining it with finasteride might slow down any upregulation.

AnagenInc is ready to produce a hair loss treatment called GT20029 if there is enough demand. People are discussing combining it with other treatments like finasteride and minoxidil, and some are concerned about the legitimacy and safety of gray market products.

The user started using topical latanoprost and dutasteride, experiencing significant hair shedding and scalp itchiness, possibly due to an allergic reaction. They are considering stopping the treatment if the shedding is linked to an allergy.

The conversation discusses the potential of a new hair loss treatment, GT20029, which targets androgen receptors in the scalp and is in phase 1 trials in China. Users express hope that this treatment will be more effective than current options like Minoxidil and Finasteride.

The user started finasteride two weeks ago and has been using minoxidil for over a month, while also supplementing with Acetyl L-Carnitine. They are curious if others have experienced hair shedding or growth with Acetyl L-Carnitine, especially when used with finasteride and minoxidil.

TDM-105795 showed promising hair growth results, with higher efficacy than placebo and minimal side effects. It activates dormant hair follicle stem cells and may maintain gains without immediate loss, unlike minoxidil.

The post discusses the user's experience with hair loss treatment RU58841, which was tested for quality and found to be 96+% pure. The conversation includes various responses, with some users questioning the safety of the product and others expressing satisfaction with the test results.

Using PP405 and Clascoterone after a hair transplant may not cause issues if the transplant didn't achieve native density, but could lead to competition for blood supply if it did. Some users suggest waiting for these drugs to be available, as they might not significantly impact blood supply or regrowth.

Copper peptide topical is being discussed for hair health, with some users noting it may improve hair volume. There is uncertainty about its effectiveness against hair loss.

An arthritis drug, baricitinib, is discussed as a potential treatment for autoimmune alopecia, not androgenetic alopecia. Ritlecitinib is also mentioned as a possible treatment for scarring alopecia.

Hair loss discussion includes treatments like Minoxidil, finasteride, and RU58841. Conversation focuses on foods with sufficient procyanidin b2, such as dark chocolate and apples, and the required dosage.

New product Tomorrowlabs HSF targets hair loss through HIF pathway indirectly by removing scalp iron. Minoxidil and Stemoxydine also relate to HIF pathway.

People are discussing their reactions if PP405 fails in phase 3 trials, with some expressing skepticism and others holding onto hope for future treatments like GT20029 and Breezula. Many mention continuing with existing treatments like minoxidil and finasteride, while others express disappointment and consider alternative solutions.